Main navigation

• Home
• Our medicines
• Diseases and conditions
• Community support
• Help affording your medicines
• Research & development
• Healthcare professionals
• Careers
• About AstraZeneca US
  • Our company
  • AZ on the issues
  • Investors
  • Responsible business
  • Newsroom
    • All news
    • Corporate news
    • Financial news
    • Product news
    • Research news
    • Media resources
  • US web sites
  • Social media sites
  • Contact us

You are here

• Home
• About AstraZeneca US
• Newsroom

• News

The following shows headlines of news articles, starting from most recent.

• Pages
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• Next

• • Mar 14, 2010
  • New analysis of JUPITER study evaluates link between high baseline levels of hsCRP and increased risk of cardiovascular events  
• • Mar 11, 2010
  • AstraZeneca comments on FDA Joint Advisory Committee meeting on post-marketing safety studies for the use of LABAs in asthma  
• • Mar 9, 2010
  • Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)  
• • Mar 3, 2010
  • AstraZeneca recognized for support of women executives  
• • Mar 1, 2010
  • AstraZeneca outlines principles for product-related online communications  
• • Feb 18, 2010
  • AstraZeneca receives prestigious CEO Cancer Gold Standard™ reaccreditation  
• • Feb 16, 2010
  • AstraZeneca prescription savings programs help more patients in 2009  
• • Feb 12, 2010
  • AstraZeneca statement on Billy Tauzin  
• • Feb 8, 2010
  • US FDA approves new indication for CRESTOR® (rosuvastatin calcium)  
• • Jan 28, 2010
  • AstraZeneca PLC fourth quarter and full year results 2009  

• Pages
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed